Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Patients with Relapsed or Refractory KMT2A-Rearranged Acute Leukemia

WALTHAM, Mass., Dec. 6, 2022. Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials